{"brief_title": "Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma", "brief_summary": "To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).", "condition": ["Lymphoma, B-Cell"], "intervention_type": ["Drug"], "intervention_name": ["Inotuzumab ozogamicin [CMC-544]"], "description": ["CMC-544, IV, dose escalation trial"], "arm_group_label": ["Inotuzumab ozogamicin"], "criteria": "Inclusion Criteria: - Subjects who have been previously diagnosed with CD22-positive, B-cell NHL, according to WHO classification, which has progressed after at least 2 prior therapies of probable clinical benefit - At the expanded cohort, part 2 of the study, subjects must have one of the following: - Follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy - Diffuse large B-cell lymphoma - Age 18 years or older Exclusion Criteria: - Candidate for potentially curative therapies in the opinion of the investigator - Chronic lymphocytic leukemia - Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic lymphoma", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Lymphoma", "mesh_term": ["Lymphoma", "Lymphoma, Non-Hodgkin", "Lymphoma, B-Cell"], "id": "NCT00073749"}